MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Arvinas Inc

Open

SectorHealthcare

9.56 5.4

Overview

Share price change

24h

Current

Min

9.01

Max

9.59

Key metrics

By Trading Economics

Income

-144M

-61M

Sales

-166M

22M

Profit margin

-273.214

Employees

430

EBITDA

-144M

-72M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+124.1% upside

Dividends

By Dow Jones

Next Earnings

29 paź 2025

Market Stats

By TradingEconomics

Market Cap

77M

626M

Previous open

4.16

Previous close

9.56

News Sentiment

By Acuity

50%

50%

149 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Arvinas Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2025, 18:41 UTC

Major Market Movers

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

Peer Comparison

Price change

Arvinas Inc Forecast

Price Target

By TipRanks

124.1% upside

12 Months Forecast

Average 20.46 USD  124.1%

High 110 USD

Low 9 USD

Based on 16 Wall Street analysts offering 12 month price targets forArvinas Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

10

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

6.55 / 9.11Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

149 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat